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Abstract
Background: Current projections of the scale of the coming dementia epidemic assume that the age- and
sex-specific prevalence of dementia will not vary over time, and that population ageing alone (increasing the
number of older people at risk) drives the projected increases. The basis for this assumption is doubtful, and
secular trends (that is, gradual decreases or increases in prevalence over long-term periods) are perfectly plausible.
Methods: We carried out a systematic review of studies of trends in prevalence, incidence and mortality for people
with dementia, conducted since 1980.
Results: We identified nine studies that had tracked dementia prevalence, eight that had tracked dementia incidence,
and four that had tracked mortality among people with dementia. There was some moderately consistent
evidence to suggest that the incidence of dementia may be declining in high-income countries. Evidence on
trends in the prevalence of dementia were inconsistent across studies and did not suggest any clear overall
effect. Declining incidence may be balanced by longer survival with dementia, although mortality trends have
been little studied. There is some evidence to suggest increasing prevalence in East Asia, consistent with
worsening cardiovascular risk factor profiles, although secular changes in diagnostic criteria may also have
contributed.
Conclusions: We found no evidence to suggest that the current assumption of constant age-specific prevalence of
dementia over time is ill-founded. However, there remains some uncertainty as to the future scale of the dementia
epidemic. Population ageing seems destined to play the greatest role, and prudent policymakers should plan future
service provision based upon current prevalence projections. Additional priorities should include investing in brain
health promotion and dementia prevention programs, and monitoring the future course of the epidemic to chart the
effectiveness of these measures.
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Background
Almost all current projections of the scale of the com-
ing dementia epidemic, including those published by
Alzheimer’s Disease International (ADI) [1–3], assume
that the age- and sex-specific prevalence of dementia
will not vary over time, and that population ageing
alone (increasing the number of older people at risk)
drives the projected increases [1, 2, 4, 5]. The basis for
this assumption is doubtful, and secular trends (that is,
gradual decreases or increases in prevalence over long-
term periods) are perfectly plausible [6]. The prevalence
of any condition (the proportion of the population af-
fected at a point in time) is a product of its incidence
and the average duration of the disease episode. The
incidence is the rate at which new cases develop within
the population. The duration of dementia equates to time
from incidence to death, given that recovery is, sadly, not
possible. Changes in either or both of these indicators
could lead to changes in age-specific prevalence [1].
* Correspondence: martin.prince@kcl.ac.uk
1The Global Observatory for Ageing and Dementia Care, Health Service &
Population Research Department, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, PO 36, David Goldberg Centre, De
Crespigny Park, London SE5 8AF, UK
Full list of author information is available at the end of the article
© 2016 Prince et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Prince et al. Alzheimer's Research & Therapy  (2016) 8:23 
DOI 10.1186/s13195-016-0188-8
It should be noted that trends in the two indicators
may not move in the same direction; for example, reduc-
tions in incidence might be accompanied by increases in
duration of survival with dementia, or vice versa, the
one effect tending to cancel out the other in terms of
their overall impact on prevalence. Secular trends may
vary among world regions, and among different popula-
tion subgroups within one country. Experience with chan-
ging rates of cardiovascular disease, obesity, diabetes and
cancer shows this clearly. Geographic or year of birth
variations in adult disease occurrence can be explained by
differential exposure during different epochs in life, since
as early as conception. Hence, the considerable variability
in secular trends for these chronic diseases reflects differ-
ent degrees of progress in improving public health and
access to healthcare, and in strengthening health sys-
tems and services to better detect, treat and control
these conditions.
A decline in age-specific incidence of dementia, at least
in high-income countries, is theoretically possible, driven
by changes in exposure to suspected developmental, life-
style and cardiovascular risk factors for dementia [6]. The
2014 World Alzheimer Report focused upon dementia
risk reduction, examining the evidence base for modifiable
risk factors for dementia [7]. The strongest evidence for
possible causal associations with dementia was for low
education in early life, hypertension in midlife, and smok-
ing and diabetes across the life course. In a recent model-
ling exercise, it was estimated that a 10 % reduction in
these and other key risk exposures would lead to an 8.3 %
reduction in the prevalence of dementia through 2050,
with a 15.3 % reduction in dementia prevalence antici-
pated in response to a 20 % reduction in exposure preva-
lence [8]. In most world regions, each generation is better
educated than the one before. Although trends differ be-
tween countries, sexes, age groups and time periods, there
has been a general trend in many high-income countries
towards less smoking, falling total cholesterol and blood
pressure levels, and increasing physical activity [9]. On
the other hand, the prevalence of obesity and diabetes
has been increasing in most developed countries. The
picture in many low- and middle-income countries is
quite different: The trends in cardiovascular health among
older people are in an adverse direction [9], with a pattern
of increasing stroke [10] and ischaemic heart disease mor-
bidity and mortality [11–13], linked to an epidemic of
obesity and increasing blood pressure levels [14]. After a
lag period, to the extent that these factors are genuinely
causally associated with dementia, one would expect to
see corresponding reductions (or increases) in the inci-
dence of dementia.
Secular trends in survival with dementia are difficult
to measure. Because dementia has a long and highly
variable latency period, estimates from clinical services
are confounded by time of diagnosis. If diagnosis is being
made at an earlier stage in the disease process, then dur-
ation of dementia may appear to be increasing, whereas
this may signify only that people with dementia are in
contact with services for a higher proportion of the overall
disease duration. Trends in cause of death on death certif-
icates provide information on secular changes in the attri-
bution of dementia as a cause of death, but not on the
all-cause mortality rate among people with dementia
[15]. A proper understanding of trends in survival with
dementia will come only from monitoring all-cause
mortality rates of those with and without the disease,
and the ratio between them (standardised mortality ra-
tio, or hazard ratio) over time. Mortality rates among
older people continue to fall in all world regions, and
for all age groups, accounting for impressive gains in
life expectancy from age 60 years [16]. This is now one
of the main drivers of population ageing, particularly
but not exclusively in higher-income countries. Whether
these overall trends for declining mortality apply equally
to people living with dementia is not known. Mortality
rates among older people are much higher for those living
with dementia. In the 10/66 Dementia Research Group
studies in Latin America, India and China, after control-
ling for age and sex, in a Cox proportional hazards regres-
sion, hazard of death was 1.56 to 5.69 times higher in
those with dementia (meta-analysed HR 2.80, 95 % CI
2.48–3.15) [17]. Effect sizes from studies in countries with
low or middle incomes (for example, HR 2.83 [95 % CI
1.10–7.27] in Nigeria [18] and HR 5.16 [95 % CI 3.74–
7.12] in Brazil [19]) have tended to be slightly higher than
those indicated by a meta-analysis of studies principally
from countries with high incomes (relative risk 2.63, 95 %
CI 2.17–3.21) [20]. If age-standardised mortality rates
among people with dementia decline at the same rate as
for those without dementia (that is, the adjusted mortality
ratio remains constant over time), survival with dementia,
and hence disease duration, will increase progressively.
Finally, it should be noted that one of the indications
of successful dementia risk reduction may be that the
incidence of dementia is deferred to older ages. Thus,
the average age of onset may increase over time. Under
these circumstances, age-specific or age-standardised
mortality for people with dementia may not change,
but overall, for all people with dementia, mortality may
be higher and survival with dementia shorter, reflecting
that onset is occurring closer to the ‘natural’ end of life.
Langa has described this phenomenon as ‘the compres-
sion of cognitive morbidity’ [21], a desirable outcome
for public health and individual quality of life, resulting
in longer, healthier lives, with fewer years spent in a
state of reduced independence and needing care.
At the time of the 2009 World Alzheimer Report, what
very few data were available from certain high-income
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countries did not suggest any clear pattern of a decline
or increase over time in either the incidence or prevalence
of dementia [1, 22, 23]. Our meta-analysis of European
studies conducted since 1980 also did not suggest any
secular trend in prevalence [4]. Just a few years later, and
linked to a greatly increased interest in the potential for
prevention of dementia by targeting modifiable risk factors
[24, 25], the quality and extent of the evidence has ex-
panded greatly, with reports from several studies of trends
in dementia prevalence, incidence and/or mortality within
defined populations. Such secular comparisons are con-
ceivably more valid because identical or very similar re-
search methodology has been applied within studies over
time. Our aim in this paper is to review this evidence,
together with regional meta-analyses of trends in demen-
tia prevalence over time. A preliminary version of this
review was published in the World Alzheimer Report
2015 [3]. The present version is substantially updated,
taking account of studies published since then and other
conference abstracts that have now been published as
definitive peer-reviewed papers, with different, and, pre-
sumably, more appropriate results.
Methods
Studies of secular trends since 1980 in the prevalence
or incidence of dementia or Alzheimer’s disease within
defined populations were identified from the systematic
review of studies of dementia prevalence and incidence
conducted by the Global Observatory for Ageing and
Dementia Care for the World Alzheimer Reports of 2009
[1] and 2015 [3], and from the World Health Organization
2012 report [26], as well as by hand-searching the refer-
ences of those relevant studies identified. Any studies that
met the sampling and ascertainment eligibility criteria for
the reviews of prevalence and incidence were included in
this review, with the additional inclusion criterion that
methodologies within studies should have been held con-
stant between successive prevalence or incidence waves.
We did not stipulate any minimum or maximum interval
between waves. We report the crude percentage reduction
or increase in prevalence or incidence, and rate of change
per year, together with adjusted rate ratios (or hazard or
odds ratios) if provided, with adjustment for compos-
itional factors, principally age and sex. For mortality, we
conducted an additional search of the PubMed database
using the search terms “(dementia or alzheim*) AND
(mortality or survival) AND trend*”.
Results
Dementia prevalence
We identified nine studies that had tracked changes in
dementia prevalence over time (Table 1). In one study,
the Medical Research Council Cognitive function and
Ageing Study (MRC CFAS) [27], there was a statistically
significant decline in the prevalence of dementia between
1993 and 2011. This was consistent with a somewhat lar-
ger but statistically non-significant decline in the preva-
lence of dementia in Zaragoza, Spain [28], and with a
decline in the prevalence of moderate to severe cognitive
impairment seen in the Health and Retirement Study
(HRS) in the United States [21]. The annual rates of rela-
tive change in prevalence were −1.7 %, −3.6 % and −3.2 %
per year, respectively. Set against this, three other studies
from Sweden [29, 30] and the United States [31] indicated
a stable prevalence of dementia, consistent with short-
term trends in German insurance claims data [32]. In a
third Swedish study of short-term trends in dementia
prevalence among the oldest old, prevalence had increased
by 40 % between 2001 and 2006 [33]. In the Japanese
Hisayama study, there was a non-significant 38 % relative
increase in the prevalence of dementia between 1985 and
2005, with a marked increase in the proportion of cases
accounted for by Alzheimer’s disease [34]. This is consist-
ent with findings from one other Japanese study of secular
trends, with a 23 % increase in the prevalence of dementia
between 1980 and 2000 [35]. This study was excluded
from this review because its ascertainment procedures did
not meet the minimum quality criteria we set for our
global estimates of dementia prevalence [1]. However,
although inadequate, they were held constant between
the three waves of the study.
Dementia incidence
Nine studies had tracked dementia incidence over time
(Table 2). Statistically significant reductions in the inci-
dence of dementia were reported in two U.S. population-
based studies: one of African Americans in Indianapolis,
IN [36] and the other derived from the Framingham study
[37]. Dementia incidence over time was also tracked in
one study done in Bordeaux, France [38]. The annual rates
of relative change (−5.5 %, −1.6 % and −3.5 %, respect-
ively) are broadly consistent with a non-significant −2.5 %
annual rate of relative change in incidence reported in the
Rotterdam study [39]. A similar annual rate of decline in
dementia incidence (−3.0 %) was reported in an analysis
of German insurance claims data [40], but with only a
3-year interval between the midpoints of the two
follow-up periods and with a possibility that trends in
help-seeking or clinical diagnosis might have explained
the findings. A similar study using comprehensive health
information system data for the Canadian province of
Ontario suggested a −0.6 % decline in standardised inci-
dence over a 12-year period (2002–2013) [41]. To the
extent that changes in incidence can be inferred from
changes in prevalence and mortality, data from repeated
surveys in Stockholm, Sweden, are also consistent with a
decline in dementia incidence [29]. On the other hand,
population-based studies conducted in Chicago, IL, USA
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Table 1 Studies estimating changes in prevalence of dementia or Alzheimer’s disease over time
Study, setting, age range Outcomes Relative change (%) Period Interval
(years)
Relative change
(%) per year
Other findings/notes
1. United Kingdom, MRC CFAS,
65 years and older [27]
Dementia (GMS-
AGECAT)
30 % reduction AOR 0.7 (0.6–0.9) 1993–2011 18 years −1.7 % Bigger dementia prevalence reduction in older
age groups. Reduction in the proportion of
older people, and people with dementia living
in care homes. Increased prevalence of
dementia among care home residents.
2. Zaragoza, Spain, 65 years
and older [28]
Dementia (DSM-IV) Non–significant 25 % reduction
AOR 0.75 (0.56–1.02)
Women AOR 1.02 (0.69–1.51)
Men AOR 0.40 (0.25–0.65)
1988–1995 7 years −3.6 % Bigger (and statistically significant) dementia
prevalence reduction in men. No changes
observed in education level.
3. HRS, nationally representative,
United States, 70 years and older
[21]
Moderate/severe
cognitive impairment
(probable dementia)
29 % reduction AOR 0.65 (0.58–0.73) 1993–2002 9 years −3.2 % Increases in levels of education, significantly
fewer IADL limitations but higher rates of
cardiovascular risk factors and cardiovascular
disease, including diabetes, hypertension,
obesity and heart disease. Education
differences accounted for 43 % of the
prevalence difference between time points.
Residents of care homes were excluded from
the 1993 wave. The 6.2 % of 2002 respondents
who were residents of care homes were also
excluded from the comparative analysis. This
may have biased the comparison, if transition
to care homes was reserved for those with
more severe dementia at the later time point.
4. United States, Indianapolis, IN,
African Americans, 65 years and
older [31]
Dementia (DSM-III-R)
AD
Stable 6.8 % vs. 7.5 % (dementia
p = 0.35) 5.5 % vs. 6.8 % (AD p = 0.26)
1991–2002 11 years No trend Increases in levels of hypertension, diabetes
and stroke, but also higher levels of treatment,
consistent with national trends for African
Americans over this time period. Some
differences in recruitment procedures, and a
higher refusal rate in 2002.
5. Stockholm, Sweden, 75 years
and older [29]
Dementia (DSM-III-R) Stable 17.5 % vs. 17.9 % AOR 0.85
(0.68–1.05)
1988–2002 14 years No trend Much higher levels of education at the second
time point.
6. Germany, insurance claims
data, 65 and older [32]
Dementia (ICD-10) Stable prevalence in all age groups and
both sexes, other than women aged
75–84 years AOR 0.97 (0.95–0.98)
2007–2009 3 years −1.2 % (women
aged 75–84 years)
This study used claims data of the largest
public health insurance company in Germany.
The data contained complete inpatient and
outpatient diagnoses according to ICD-10.
For the analysis of prevalence, age-specific
prevalence was estimated for the years 2007,
2008 and 2009. Secular trends in clinical
diagnosis or help-seeking cannot be excluded.
7. Goteborg, Sweden, aged 70
and 75 years [30]
Dementia historical
criteria
Stable prevalence for both age groups
Age 70 years M 1.7 % vs. 0.9 % F 2.2 %
vs. 3.7 % Age 75 years M 6.8 % vs. 6.9 %
F 3.8 % vs. 5.3 %
Aged 70 years
1976–2000
Aged 75 years
1976–2005
Aged 70 years
25 years
Aged 75 years
30 years
No trend Higher education level, better results on
cognitive tests, better socioeconomic status,
better treatment of vascular risk factors and
better general physical health in the later-born
cohorts
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Table 1 Studies estimating changes in prevalence of dementia or Alzheimer’s disease over time (Continued)
8. Umea, Sweden, 85 years and
older [33]
Dementia (DSM-IV) 40 % increase (p = 0.001) 2001–2006 5 years +8.0 % Prevalence differences not adjusted for other
covariates, but age distribution was similar.
Increase in the prescription of antihypertensive
and statin drugs, cholinesterase inhibitors, and
more heart surgery.
9. Japan, Hisayama, aged
65 years and older [34]
Dementia, AD 38 % increase (dementia) AOR 1.34
(0.97–1.87) 255 % increase (AD) 3.28
(1.75–6.14)
1985–2005 20 years +1.9 % (dementia)
+ 12.8 % (AD)
Ratio of AD/VaD increasing from 0.5 in
1985 to 1.4 in 2005.
AD Alzheimer’s disease, AGECAT Automated Geriatric Examination for Computer Assisted Taxonomy, AOR adjusted odds ratio, DSM Diagnostic and Statistical Manual of Mental Disorders, GMS Geriatric Mental State
Examination, HRS Health and Retirement Study, IADL instrumental activities of daily living, ICD International Classification of Diseases, MRC CFAS Medical Research Council Cognitive function and Ageing Study,
VaD vascular dementia
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Table 2 Studies estimating changes in the incidence of dementia or Alzheimer’s disease over time
Study, setting, age range Outcomes Relative change (%) Period Interval between
incidence cohorts
(years)
Relative change
(%) per year
Other findings
Directly observed
1. Indianapolis, IN, USA,
African Americans, 65 years
and older [36]
Dementia (DSM-III-R)
AD
Dementia
3.6 % per annum (3.2–4.1 %) vs.
1.4 % per annum (1.2–1.7 %)
61 % reduction
AD
2.5 % per annum (2.1–2.9 %) vs.
1.3 % per annum (1.0–1.5 %)
48 % reduction
1991–2002 11 years Dementia
−5.5 %
AD
−4.4 %
Biggest reduction in youngest age groups.
See also notes for study 4 in Table 1.
2. Framingham, MA, USA,
60 years and older [37]
Dementia DSM-IV
AD (NINCDS-ADRDA)
VaD (NINDS-AIREN);
diagnoses by consensus
review panel
Dementia
44 % reduction
AHR 0.56 (0.41–0.77)
AD
30 % reduction
AHR 0.70 (0.48–1.03)
VaD
55 % reduction
AHR 0.45 (0.23–0.87)
1980–2006 26 years Dementia
−1.7 %
AD
−1.2 %
VaD
−2.1 %
Biggest reduction in youngest age groups.
No reduction among the least educated.
Significant improvements in education status;
use of antihypertensive and statin medication;
blood pressure and HDL levels; and prevalence
of smoking, heart disease and stroke; however,
prevalence of obesity and diabetes increased.
3. Bordeaux, France, 65 years
and older [38]
Algorithm diagnosis
(using MMSE score
and IADL only)
Clinical diagnosis
‘based upon’
DSM-IIIR/DSM-V
Algorithmic diagnosis
Overall AHR 0.65 (0.53–0.81)
Women AHR 0.62 (0.48–0.80)
Men AHR 1.10 (0.69–1.78)
Clinical diagnosis
Overall 0.92 (0.73–1.15)
Women 0.90 (0.69–1.17)
Men 1.21 (0.76–1.93).
1988/1989–1998/
1999 and 1999/
2001– 2009/2010
10 years Overall
−3.5 %
Women
−3.8 %
Compared with the earlier cohort, the later
cohort had more education, a higher BMI, a
lower prevalence of stroke, and were less
likely to be a current and more likely to be
former smokers. More use of antihypertensive
and lipid-lowering drugs. At baseline, they
were less disabled on the 4-item IADL score
and had higher MMSE scores.
Differences in education, vascular factors and
depression accounted only to some extent
for this reduction (overall AHR 0.77, 95 % CI
0.61–0.97; women AHR 0.73, 95 % CI 0.57–0.95).
4. Rotterdam, the Netherlands, 60–
90 years [39]
Dementia (DSM-III-R) Non-significant 25 % reduction
RR 0.75 (0.56–1.02)
1990–2000 10 years −2.5 % Hypertension, diabetes and obesity increased.
Higher education. More diabetes treatment,
more anti-thrombotics and much more
statins. More past but less current smoking.
Substantial reduction in overall mortality:
HR 0.63 (0.52–0.77).
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Table 2 Studies estimating changes in the incidence of dementia or Alzheimer’s disease over time (Continued)
5. Germany, insurance claims
data, 65 years and older [40]
Dementia (ICD-10), or
using cholinesterase
inhibitors or memantine
9 % reduction
Men 0.91 (0.85–0.97)
Women 0.91 (0.87–0.95)
2004–2007/
2007–2010
3 years −3.0 % This study used claims data of the largest
public health insurance company in Germany.
The data contained complete inpatient and
outpatient diagnoses according to ICD-10
codes. For the analysis of incidence, two
independent age-stratified samples were
taken, the first comprising 139,617 persons
in 2004 with follow-up until 2007, the
second with 134,653 persons in 2007 with
follow-up until 2010. Secular trends in
clinical diagnosis or help-seeking cannot
be excluded.
6. Ontario, Canada; health
insurance plan, hospital
discharge and ambulatory
care register; age range not
reported [41]
Dementia diagnosis
(ICD-9 or ICD-10) or
cholinesterase inhibitor
prescription
7.4 % reduction; statistical
significance of trend not
reported
2002–2013 12 years −0.6 % This study used claims data of the single
state-provided insurance plan and
comprehensive hospital admission,
ambulatory care and drug prescription
databases. Annual incidence rates, age- and
sex-standardised, are reported for each year
between 2002 and 2013. The trend is not
linear, and statistical significance is not
reported. Secular trends in clinical diagnosis
or help-seeking cannot be excluded.
7. Chicago, IL, USA [31] AD Stable
OR 0.97 (0.90–1.04)
1997–2008 11 years No trend
8. Ibadan, Nigeria [52] Dementia (DSM-III-R)
AD
Stable
Dementia
1.7 % per annum (1.4–2.0 %) vs.
1.4 % per annum (1.1–1.6 %)
AD
1.5 % per annum (1.2–1.8 %) vs.
1.0 % (0.7–1.2 %)
1991–2002 11 years No trend
Inferred
9. Stockholm, Sweden,
75 years and older [29]
Dementia (DSM-III-R) Reduced incidence inferred
from stable prevalence but
increased survival with dementia
1988–2002 14 years Not reported See also notes for Table 1, study 5.
AD Alzheimer’s disease, AHR adjusted hazard ratio, BMI body mass index, DSM Diagnostic and Statistical Manual of Mental Disorders, HDL high-density lipoprotein, IADL instrumental activities of daily living,
ICD International Classification of Diseases, MMSE Mini Mental State Examination, NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related
Disorders Association, NINDS-AIREN National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l’Enseignement en Neurosciences, RR relative risk, VaD vascular dementia
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[31], and Ibadan, Nigeria [36], indicated a stable incidence
of dementia over 11-year periods. One further study, in
which researchers reported a stable incidence of dementia
in Beijing, China, was excluded from the review because it
used slightly different diagnostic criteria at the two time
points [42].
Dementia mortality
In only four of the studies did the researchers take the
opportunity to study or report changes in mortality and/
or survival among people with dementia, or the ratio of
mortality rates between those with and without demen-
tia (Table 3). In the Rotterdam study [39], overall mor-
tality had declined by 37 % in the 10 years between
the two cohorts, but this was not reported with
stratification by dementia status. In the HRS in the
United States, as well as in the Stockholm study [29],
the mortality ratio for dementia remained relatively
stable over time, suggesting that, under the assumption
that mortality rates were falling among those without de-
mentia, there would have been similar rates of decline for
those living with dementia. This was clearly demonstrated
in the Stockholm study, where an absolute decline in mor-
tality rates of 30 % over 14 years was seen for those with
and without dementia, for both sexes [29]. The relation-
ship between trends in prevalence, incidence and mortal-
ity remain unclear, partly because in most of the eligible
studies only some of these parameters were directly ob-
served. Only in the German insurance claims data were
changes in prevalence, incidence and mortality reported,
but these are mutually inconsistent, perhaps because dif-
ferent samples and time periods were used for the preva-
lence [32] and incidence and/or mortality trend analyses
[40]. In marked contrast to other studies, a precipitous in-
crease in mortality rates among people with dementia,
particularly women, was noted over a short time interval
[40]. In Stockholm (where prevalence and mortality were
observed) [29], and in Indianapolis, IN, USA (where
prevalence and incidence were observed) [31, 36], find-
ings are consistent with declining incidence but stable
prevalence, accounted for by increasing duration of de-
mentia (declining dementia mortality).
Secular trends within regions estimated from meta-analyses
of individual studies
Another approach to estimating secular trends involves
combining evidence from all studies conducted within a
particular country or region, using a meta-analytical ap-
proach and meta-regression to estimate the effect of time
of study upon prevalence. This approach was used in the
2009 ADI World Alzheimer Report to estimate secular
trends in dementia prevalence in Europe [1]. One problem
with such exercises is that, in contrast to the studies previ-
ously reviewed, which hold such factors constant, there is
inevitably considerable heterogeneity in the nature of the
population studied and the methods used for the surveys,
which may in turn affect the prevalence recorded. It is
therefore important, to the extent possible, to control for
such effects in the meta-regression. In the European
meta-analyses, there was no evidence for a trend in preva-
lence between 1980 and 2008 [4], and this held true when
the evidence base was updated to include studies con-
ducted through 2015 for the 2015 World Alzheimer
Report [3].
East Asia is the one other world region with sufficiently
numerous prevalence studies to permit meta-regression
and estimation of secular trends in dementia prevalence. A
study of secular trends in Japan (part of the adjacent Asia
Pacific high-income region) reported a tendency towards
increasing prevalence, but this was based on only eight data
points, including the four waves of the Hisayama study
[34], and did not control for study methodology [43]. A sys-
tematic review and meta-analysis of 11 population-based
prevalence studies conducted in South Korea since 1990
identified a trend towards a decrease in the prevalence of
dementia until 2000–2005, with a subsequent increase, but
with no statistically significant temporal variation, having
adjusted for sample composition and study methodological
quality [44]. The East Asia evidence base and the popula-
tion of older people at risk is dominated by China, the focus
of one recent meta-analysis [45], while a second meta-
analysis also included studies conducted in Hong Kong and
Taiwan [46]. Estimates taken from the China meta-analysis
suggested a 46 % relative increase in age-standardised
prevalence from 1990 to 2010 (+2.3 % per year), while in
the wider review the increase was 171 % from studies con-
ducted in the pre-1990 period to 2005–2012 (a prevalence
of 2.1 % pre-1990, 3.4 % for 1990–1994, 3.9 % for 1995–
1999, 4.4 % for 2000–2004 and 5.7 % for 2005–2012).
However, in that study, the secular trend was consider-
ably reduced, to 72 %, and was no longer statistically
significant, having controlled for study methodology
(1.8 % pre-1990, 2.5 % for 1990–1994, 2.1 % for 1995–
1999, 2.4 % for 2000–2004 and 3.1 % for 2005–2012).
The most important potential confounder appeared
to be the choice of dementia diagnostic criteria. Older
studies tended to use criteria from the Diagnostic and
Statistical Manual of Mental Disorders, Third Edition
(DSM-III), the DSM-III-R, or the International Classifi-
cation of Diseases, Tenth Revision, which then tended
to record a lower prevalence of dementia than those
more recent studies that used DSM-IV dementia, 10/66
dementia criteria or Geriatric Mental State Examination
(GMS)-Automated Geriatric Examination for Computer
Assisted Taxonomy (AGECAT) criteria. For the purposes
of estimating current dementia prevalence, whether the
higher estimates for the most recent period are explained
by real underlying secular trends or the use of more up-
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Table 3 Changes in mortality among people with dementia
Study, setting, age range Outcomes Change in mortality and/or mortality hazard
ratio
Period Interval
(years)
Other findings/notes
Directly observed
1. United States, HRS [21] Mortality hazard ratio Non-significant increase, from HR 2.53 to 3.11,
p = 0.09
1993–2002 9 years No report of absolute mortality rates, stratified or unstratified.
However, given a presumed decline in overall mortality, it
seems likely that mortality also declined among people with
dementia, but to a slightly lesser extent
2. Stockholm, Sweden [29] Mortality hazard ratio Stable HR: 2.42 (2.03–2.87) vs. 2.47 (2.03–3.00) 1988–2002 14 years Secular trend similar (30 % reduction in mortality) to that for
those with no dementia, and for both sexes
Mortality rate among people
with dementia
29 % reduction in mortality (HR 0.71, 95 % CI
0.57–0.88) adjusted for age, sex, education
and MMSE score
3. Germany, insurance claims
data, 65 years and older [32]
Mortality rate among people
with dementia
20 % increase in mortality among women
with dementia (p < 0.0001)
Non-significant 11 % increase in mortality
among men with dementia (p = 0.75)
2004–2007 3 years Mortality among women without dementia remained
constant over the two cohorts, while there was a
non-significant 4 % decline in mortality rates among
men without dementia. These findings would suggest
an increase in the mortality hazard ratio associated
with dementia, greater for women than for men.
Inferred
4. Indianapolis, IN, USA, African
Americans, 65 years and older
[31, 36]
Dementia duration Increase in survival with dementia can be
inferred from stable prevalence of dementia
[31], but 55 % fall in incidence [36]
1991–2002 11 years Extrapolation from reported prevalence and incidence
rates at the two time points suggests that survival time
with dementia is 2.4 times longer for the second cohort.
MMSE Mini Mental State Examination
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to-date and valid diagnostic criteria, or both, is immaterial.
However, for the purposes of forecasting future trends in
prevalence and numbers in the region, the distinction is
clearly crucially important [47]. As previously indicated,
there is evidence that cardiovascular health is deteriorat-
ing among older people in China [11], a trend also evident
in other middle-income countries [9]. The prevalence of
smoking among adult men in China is among the highest
in the world, and an epidemic among younger women is
well underway [48]. Rapid dietary transition is leading to
an epidemic of obesity and cardiometabolic disease [49].
A recent modelling exercise assessed the likely impact of
recent increases in obesity among middle-aged Chinese
on dementia prevalence, assuming a causal link with de-
mentia. The authors of that study concluded that future
dementia prevalence in China may have been under-
estimated by up to 19 %, given the additional impact
of epidemiologic transition [50]. The relative contri-
butions of changes in diagnostic criteria, as well as
changes in risk factor exposure, both associated with
the time that the study was conducted, are uncertain
and cannot be resolved with currently available data.
Discussion
We have updated our recent work on the global burden
of dementia and reviewed the entirety of the current
global evidence on trends in the prevalence, incidence,
and survival with or mortality due to dementia, using
data from studies in which investigators had monitored
these indicators over time in defined populations with
fixed survey and dementia ascertainment methodologies.
We also reviewed regional meta-analyses in which re-
searchers had sought to estimate regional trends in preva-
lence across studies, conducted in various sites and using
diverse methods. The present review is the most compre-
hensive such study to date.
There is no clear evidence from this review to justify a
departure from the current position of assuming constant
age-specific dementia prevalence when making projec-
tions of the numbers likely to be affected in the future [3].
The evidence for a declining trend in the incidence of
dementia, at least in high-income countries, is somewhat
more consistent, although still patchy, and as yet thinly
evidenced. Although the evidence on changes in survival
in those with dementia is extremely limited, it is plausible
that the effects of a reduced incidence upon prevalence
are likely to be offset by a longer survival of those living
with dementia.
Potential for prevention
The future course of the global dementia epidemic
through to 2050 is likely to depend, at least to some
extent, upon the success or otherwise of continuing ef-
forts to improve public health [7, 25]. Those who will be
old in 2050 were born around the 1970s and have
already received their basic education. They are now in
their fourth and fifth decades of life, a crucial ‘sensitive
period’ in which evidence suggests that efforts to pre-
vent, detect and control obesity, hypertension, diabetes
and dyslipidaemia are likely to have maximum positive
impact upon brain health and dementia risk in later life
[7, 25]. Such public health strategies, alongside secular
improvements in education, are plausibly likely to result
in a progressive decline in age-specific incidence of de-
mentia in high-income countries, the magnitude of which
is currently uncertain.
The important impact of survival with dementia
Whether declining incidence is accompanied by a decline
in the age-specific prevalence of dementia will depend
upon any coincident changes in survival and/or mortality
patterns of people living with dementia, which are difficult
to predict on the basis of current data. If the onset of de-
mentia occurs close to the end of the natural lifespan,
fewer years may be lived with dementia. Two studies sug-
gest that decline in incidence may be greater in younger
age groups, suggesting that the incidence of dementia may
be being deferred into older age [51, 52]. This may be
consistent with the observation of an increasing preva-
lence of dementia among the oldest old in one Swedish
study [33], but it is inconsistent with the observation from
the MRC CFAS study of greater reductions of dementia
prevalence among older age groups [27]. Since most of
the public health interventions that have been proposed to
reduce the incidence of dementia (for example, tobacco
control, and prevention and treatment of hypertension)
also have benefits in reducing incidence and mortality due
to other chronic diseases, one should expect that reduc-
tions in prevalence arising from reduced incidence of
dementia may be offset, at least to some extent, by re-
duced mortality and longer survival with dementia [53].
Most of the more plausible scenarios are more consistent
with either a stable or a modestly increasing disease preva-
lence [53, 54]. Of concern, current evidence of adverse
trends in cardiovascular risk factors and morbidity in low-
and middle-income countries are consistent with a future
increase in age-specific incidence and prevalence of
dementia in those regions.
Other factors, such as improvements in standards of
health and social care for people with dementia as well
as provision or withholding of life-prolonging critical in-
terventions, might also be expected to have an influence
on mortality rates among people living with dementia.
In well-resourced, advanced healthcare settings, there is
growing awareness that critical interventions should not
be withheld simply because someone has dementia when
these would improve quality of life. At the same time, in
the context of end-of-life care, the focus should be on
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palliation to improve quality of life, and interventions
that merely prolong life with risk of harm to the patient
should be withheld [55]. In low- and middle-income
countries, there is evidence that people with dementia
currently have particular problems in accessing health-
care that might benefit their health and survival [56].
Implications for future research
Studies that use fixed methodology to estimate changes
in dementia prevalence, incidence and mortality over time,
in defined populations, are uniquely valuable assets. It is
important that more such studies be commissioned. The
most valuable will be those that track all three parameters
over time, which none of the studies reviewed in this
paper did. Surveys with nationally representative samples
will have the greatest generalisability and the greatest po-
tential to both inform and track the impact of national
policies. Where trends are observed, it will be important
to relate these to compositional changes in the population,
particularly to changes in levels of exposure to critical risk
factors. However, in very few studies have researchers
made a comprehensive assessment of such compositional
factors and their changes over time, and in only three
studies did investigators attempt to attribute changes in
dementia frequency to changes in risk factor exposure
[21, 37, 38]. It is clearly important that such studies do,
as far as possible, hold methodology constant. Several
of those reviewed here did make small changes between
waves, the effect of which upon the observed trends
cannot be determined with complete confidence [27, 31].
Diagnostic criteria change over time, but these too must
be held constant to make meaningful comparisons, a
problem that can be surmounted by using the updated
criteria alongside the original criteria, where feasible
and appropriate. A more intractable problem is the
probable changes in clinician training, practice and
opinions regarding the operationalisation of diagnostic
criteria [38, 47]. This may also be countered through
the application of structured assessments and diagnostic
algorithms, such as the AGECAT computerised algorithm
linked to the Geriatric Mental State [57], as employed in
the MRC CFAS studies [27], or the 10/66 Dementia Re-
search Group’s cross-culturally validated diagnostic algo-
rithm [58, 59]. Finally, the potential for selection bias due
to declining participation rates and increasing attrition rates
in cohort studies needs to be carefully considered [27].
In previous modelling exercises, researchers have sought
to predict what might happen to the future prevalence of
dementia, given our best estimates of risk associations
and possible changes in those risk factor profiles over
time [8, 50]. In the light of the present review, these
estimations appear overoptimistic. An alternative ap-
proach is to observe and correlate actual changes in
risk factor profiles and dementia incidence over time.
This is a well-established modelling approach in the
cardiovascular disease field and has contributed greatly
to understanding of the potential for prevention, and
the attribution of changes in disease incidence to specific
factors, to further guide prevention strategies [60–62]. Of
note, the three studies in this review in which investigators
attempted to do this indicate that changes in education
and cardiovascular risk account for only a modest pro-
portion of observed reduction in prevalence or inci-
dence [21, 37, 38]. The interesting implication would be
that other unanticipated, unmeasured and uncontrolled
secular changes in population characteristics may have
had an important impact. Similar studies should be car-
ried out in the future to monitor the impact of prevention
programs on the future scale of the dementia epidemic.
Conclusions
The best available evidence suggests that the age-specific
prevalence of dementia is unlikely to change significantly in
coming years, even if the incidence of dementia falls in re-
sponse to secular improvements in public health in high-
income countries. This conclusion remains provisional,
given the limited data available on secular trends and
the heterogeneity in study findings. Prudent policy-
makers should exercise due caution, being swayed neither
by individual studies nor by Pollyannaish statements, such
as expressed in a recent Lancet editorial [63]:
The projections of the ADI report for 2050 are
alarming, but it is important to bear in mind that
they are just that – projections.... The opportunity is
here to ensure that the grim outlook for dementia in
2050, especially in low-income and middle-income
countries, becomes nothing more than a work of
fiction.
Future projections [3] may actually turn out to be con-
servative, particularly for low- and middle-income coun-
tries, should effective public health action not be taken.
Under currently foreseeable scenarios, they should be con-
sidered as constituting the mid range of expectations.
More research into national and regional trends in disease
frequency, linked to changes in exposure levels to known
risk factors, is urgently required.
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